Division of Gastroenterology & Hepatology Research
Our research goals at NYU Langone’s Division of Gastroenterology and Hepatology are to provide access to the latest treatments in the pipeline to our patients and to advance knowledge of gastroenterology and hepatology through innovative basic science, translational research, and clinical trials. We aim to foster a spirit of scientific inquiry and innovation among faculty, fellows, and students.
Our researchers study the biology, prevention, diagnosis, and treatment of gastrointestinal (GI) and liver diseases. Among our current areas of research are the following:
- role of the gut microbiome in health and the pathogenesis of disease such as colorectal cancer, liver cancer, and fatty liver and other diseases
- role of GI infection and gut microbial dysbiosis in the pathogenesis of inflammatory bowel disease
- quality and innovations in enhanced technologies for colon cancer screening
- bariatric endoscopy outcomes in obesity and fatty liver disease
- clinical trials in all areas of liver disease, inflammatory bowel disease, colorectal cancer screening and prevention, and other GI conditions
- cirrhosis and hepatitis C infection
Select Faculty Publications
Risk of Intestinal and Extraintestinal Malignancies in Inflammatory Bowel Disease With and Without Primary Sclerosing Cholangitis
Digestive diseases and sciences. 2025 Dec 02;
International, multicenter analysis of endoscopic full-thickness resection of duodenal neuroendocrine tumors
American journal of gastroenterology. 2025 Dec 01; 120:2800-2809
Esophageal Disorders in the Older Adult
Current treatment options in gastroenterology. 2025 Dec ; 23:
A randomized clinical trial of multi-level intervention to improve colorectal cancer screening rates at multiple federally qualified health care centers in New York City
Contemporary clinical trials. 2025 Dec ; 159:108115
Benchmarking proprietary and open-source language and vision-language models for gastroenterology clinical reasoning
NPJ digital medicine. 2025 Nov 27;
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age
Inflammatory bowel diseases. 2025 Nov 22;
Editorial: Remission Ambition-How Far Should We Push in Older Adults? Authors' Reply [Editorial]
Alimentary pharmacology & therapeutics. 2025 Nov 20;
Colorectal Cancer Screening and Mortality Trends in the United States Over 25 Years: A Story of Success and Inequity
Digestive diseases and sciences. 2025 Nov 13;